Get the Stockscreener App
23.62
2.96%
0.68
Catalyst Pharmaceuticals Inc stock is traded at $23.62, with a volume of 1.96M.
It is up +2.96% in the last 24 hours and up +3.69% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$22.94
Open:
$23.06
24h Volume:
1.96M
Relative Volume:
1.46
Market Cap:
$2.90B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
20.02
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+0.38%
1M Performance:
+3.69%
6M Performance:
-2.76%
1Y Performance:
+10.68%
1-Day Range:
$22.66
$23.84
1-Week Range:
$22.20
$23.84
52-Week Range:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
23.62 | 2.82B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Globeflex Capital L P Increases Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX) - Insider Monkey
JPMorgan Chase & Co. Buys 81,188 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals (CPRX): Valuation Check After Upbeat Quarter and Raised 2025 Sales Guidance - Sahm
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Transcript : Catalyst Pharmaceuticals, Inc. Presents at BofA Securities CNS Therapeutics Virtual Conference 2025, Dec-08-2025 12 - marketscreener.com
How Investors Are Reacting To Catalyst Pharmaceuticals (CPRX) Upgraded 2025 Sales Outlook And Easing Short Interest - Sahm
Arrowstreet Capital Limited Partnership Purchases 188,594 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue? - sharewise.com
Kennedy Capital Management LLC Cuts Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceutical (CPRX) Recently Broke Out Above the 20-Day Moving Average - Finviz
Should I hold or sell Catalyst Pharmaceuticals Inc. stock in 2025Earnings Recap Report & Fast Moving Stock Watchlists - Newser
Is There Still Value in Catalyst Pharmaceuticals After Its 540% Five Year Surge? - Yahoo Finance
Catalyst: Firdapse Cliff Deferred, But Capital Allocation Still An Issue (Upgrade) (CPRX) - Seeking Alpha
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals (CPRX) chair reports gifts of company stock to family trusts - Stock Titan
Will Catalyst Pharmaceuticals Inc. (CN2) stock sustain bullish trend into 2025Market Activity Recap & Weekly Momentum Picks - Newser
Franklin Resources Inc. Boosts Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Can Catalyst Pharmaceuticals Inc. (CN2) stock hit consensus price targetsWeekly Trend Report & Verified Short-Term Trading Plans - Newser
CPRX SEC FilingsCatalyst Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Catalyst Pharmaceuticals (CPRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Transcript : Catalyst Pharmaceuticals, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 01 - marketscreener.com
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - sharewise.com
How Catalyst Pharmaceuticals Inc. (CN2) stock behaves under inflation pressureJuly 2025 EndofMonth & High Accuracy Swing Entry Alerts - Newser
What valuation ratios show for Catalyst Pharmaceuticals Inc. (CN2) stockEarnings Recap Summary & Expert Verified Stock Movement Alerts - Newser
Catalyst Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors - 富途牛牛
Published on: 2025-12-02 00:32:14 - Newser
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - sharewise.com
How Do Investors Really Feel About Catalyst Pharmaceuticals Inc? - Benzinga
Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet - Finviz
Skandinaviska Enskilda Banken AB publ Trims Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Legal & General Group Plc Buys 89,958 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Elo Mutual Pension Insurance Co Takes $605,000 Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by American Century Companies Inc. - MarketBeat
Carmen Jeffrey Del Sells 10,983 Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock - MarketBeat
Catalyst Pharmaceuticals Executive Sells Shares - TradingView
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Advisors Asset Management Inc. - MarketBeat
A Fresh Look at Catalyst Pharmaceuticals (CPRX) Valuation Following Recent Share Price Momentum - Yahoo Finance
Catalyst Pharmaceuticals (CPRX): Assessing Valuation After Recent Share Price Gains and Pipeline Developments - Sahm
Catalyst Pharmaceuticals, Inc. $CPRX Stake Decreased by Segall Bryant & Hamill LLC - MarketBeat
Will Catalyst Pharmaceuticals Inc. stock deliver strong dividend growth2025 Market Trends & Consistent Return Strategy Ideas - moha.gov.vn
Will Catalyst Pharmaceuticals Inc. stock see insider buyingGap Down & Weekly High Return Stock Opportunities - moha.gov.vn
Summit Global Investments Reduces Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Reduces Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Magnetar Financial LLC Buys New Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Purchased by Geode Capital Management LLC - MarketBeat
CFO Kalb Acquires 4,409 Of Catalyst Pharmaceuticals Inc [CPRX] - TradingView
CEO Daly Acquires 12,134 Of Catalyst Pharmaceuticals Inc [CPRX] - TradingView
Officer Sundaram Acquires 4,239 Of Catalyst Pharmaceuticals Inc [CPRX] - TradingView
Officer del Carmen Acquires 3,962 Of Catalyst Pharmaceuticals Inc [CPRX] - TradingView
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):